In January 2017, Alexion Pharmaceuticals, Amicus Therapeutics and Sanofi Genzyme joined the Rare Disease Action Forum (RDAF). With this growth, the Forum now includes eight member companies that are all important contributors in the field of rare diseases. Using a multi-stakeholder approach, the RDAF aims at developing and implementing solutions to improve access to diagnosis and treatment for patients with rare diseases in Switzerland. Press release (PDF): English, German, French, Italian
RDAF hosts multi-stakeholder workshop on post-marketing registries
The Rare Disease Action Forum (RDAF) will host a multi-stakeholder workshop on post-marketing registries for rare diseases on 21 September 2023 (14.00 – 19.00 CEST) in Basel, Switzerland. The workshop will gather stakeholders active in the rare disease field to...